Targeted Therapy Modulates the Secretome of Cancer-Associated Fibroblasts to Induce Resistance in HER2-Positive Breast Cancer

The combination of trastuzumab plus pertuzumab plus docetaxel as a first-line therapy in patients with HER2-positive metastatic breast cancer has provided significant clinical benefits compared to trastuzumab plus docetaxel alone. However, despite the therapeutic success of existing therapies target...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	International journal of molecular sciences 2021-12, Vol.22 (24), p.13297, Article 13297
Hauptverfasser:	Luque, Melani, Sanz-Alvarez, Marta, Santamaria, Andrea, Zazo, Sandra, Cristobal, Ion, de la Fuente, Lorena, Minguez, Pablo, Eroles, Pilar, Rovira, Ana, Albanell, Joan, Madoz-Gurpide, Juan, Rojo, Federico
Format:	Artikel
Sprache:	eng
Schlagworte:	Antibodies, Monoclonal, Humanized - pharmacology Antineoplastic Combined Chemotherapy Protocols - pharmacology Biochemistry & Molecular Biology Breast cancer Breast Neoplasms - drug therapy Breast Neoplasms - metabolism Breast Neoplasms - pathology Cancer therapies Cancer-Associated Fibroblasts - metabolism Cancer-Associated Fibroblasts - pathology Cell Line, Tumor Chemistry Chemistry, Multidisciplinary Chemotherapy Cytokines Docetaxel - pharmacology Drug Delivery Systems Drug resistance Drug Resistance, Neoplasm - drug effects ErbB-2 protein Female Fibroblasts Genotype & phenotype Growth factors HER2-positive Humans Life Sciences & Biomedicine Mass spectrometry Metastases Microenvironments MicroRNAs miRNA Monoclonal antibodies Patients Phenotypes Phosphorylation Physical Sciences Proteins Receptor, ErbB-2 - metabolism resistance Science & Technology Scientific imaging Secretome Stroma Targeted cancer therapy targeted therapy Therapeutic targets Transcription factors Trastuzumab Trastuzumab - pharmacology Tumor cell lines Tumor microenvironment Tumors tumour microenvironment
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!